<SEC-DOCUMENT>0000939767-17-000136.txt : 20170802
<SEC-HEADER>0000939767-17-000136.hdr.sgml : 20170802
<ACCEPTANCE-DATETIME>20170802161152
ACCESSION NUMBER:		0000939767-17-000136
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170802
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170802
DATE AS OF CHANGE:		20170802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		171000017

	BUSINESS ADDRESS:	
		STREET 1:		210 E. GRAND AVE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		210 E. GRAND AVE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel8-kq22017earningsrelea.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA9D00C6B153D33B4E3A212B9F7E38F33"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">CURRENT REPORT </font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE </font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Date of Report (Date of earliest event reported): </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">August&#160;2, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:22pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:22pt;"><font style="font-family:inherit;font-size:22pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Exact name of registrant as specified in its charter)</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0-30235</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-3257395</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;text-indent:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(State or Other Jurisdiction  <br>of Incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;text-indent:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Commission  <br>File Number)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;text-indent:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(IRS Employer  <br>Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">210 East Grand Ave.</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">South San Francisco, CA 94080</font></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Address of principal executive offices) (Zip Code)</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(650) 837-7000</font></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Address of principal executive offices) (Zip Code)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company.    </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sAD2258F4F82E86AED66512B9F80B3D45"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations and Financial Condition.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">August&#160;2, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Exelixis issued a press release announcing its financial results for the quarter ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The information in this Item 2.02, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.3931623931624%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibits.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:64.1025641025641%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:23%;"></td><td style="width:2%;"></td><td style="width:75%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-weight:bold;">Exhibit Description</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release issued Aug 2, 2017.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sC4A5D56F4613916D763C12B9F829F1B5"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.42857142857143%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">E</font><font style="font-family:inherit;font-size:8pt;">XELIXIS, </font><font style="font-family:inherit;font-size:10pt;">I</font><font style="font-family:inherit;font-size:8pt;">NC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;2, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ J</font><font style="font-family:inherit;font-size:8pt;">EFFREY</font><font style="font-family:inherit;font-size:10pt;">&#160;J. H</font><font style="font-family:inherit;font-size:8pt;">ESSEKIEL</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Jeffrey J. Hessekiel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, General Counsel and Secretary</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sC034D499EBB6CBDEDB2812B9F85BADC1"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:59.523809523809526%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:23%;"></td><td style="width:2%;"></td><td style="width:75%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-weight:bold;">Exhibit Description</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release issued Aug 2, 2017.</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exel20170630exhibit991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEACB95577269AFDE5DD312B9E3A5397F"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:660px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><img src="exellogo2017q1a01.gif" alt="exellogo2017q1a01.gif" style="height:126px;width:200px;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contacts:</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chris Senner</font></div><div style="line-height:120%;text-align:right;padding-left:18px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer</font></div><div style="line-height:120%;text-align:right;padding-left:144px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exelixis, Inc.</font></div><div style="line-height:120%;text-align:right;padding-left:144px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(650) 837-7240</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-style:italic;text-decoration:underline;">csenner@exelixis.com</font></div><div style="line-height:120%;text-align:right;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Susan Hubbard</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Executive Vice President, </font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Public Affairs and </font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investor Relations</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exelixis, Inc.</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(650) 837-8194</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-style:italic;text-decoration:underline;">shubbard@exelixis.com</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AND PROVIDES CORPORATE UPDATE</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">- Cabozantinib Franchise Net Product Revenue of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">$88.0 million</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">, Total Revenue of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">$99.0 million</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;-</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">- Net Income of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">$17.7 million</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">, Diluted EPS of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">$0.06</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;per Share -</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">- Conference Call and Webcast Today at 5:00 PM Eastern Time -</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOUTH SAN FRANCISCO, CA - </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">August&#160;2, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exelixis is focused on maximizing the opportunity for its two internally discovered compounds, cabozantinib and cobimetinib, to improve care and outcomes for people with cancer around the world. The company&#8217;s top priority remains the commercialization of CABOMETYX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(cabozantinib) tablets as a treatment for patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. During the second quarter of 2017, CABOMETYX generated </font><font style="font-family:inherit;font-size:10pt;">$80.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net product revenue, while COMETRIQ</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(cabozantinib) capsules for the treatment of patients with progressive, metastatic medullary thyroid cancer generated an additional </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net product revenue, for a combined </font><font style="font-family:inherit;font-size:10pt;">$88.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net product revenue for the cabozantinib franchise. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While continuing to execute on the commercialization of CABOMETYX, Exelixis made further progress this quarter on drivers for the company&#8217;s future growth. Importantly, an analysis of progression-free survival (PFS) based on the independent radiology review committee (IRC) review of radiographic images from the CABOSUN trial confirmed results per investigator assessment reported earlier. The IRC review was conducted in support of a supplemental New Drug Application (sNDA) filing for cabozantinib as a treatment for patients with previously untreated advanced RCC planned for submission in the third quarter of 2017. In addition, several new trials combining cabozantinib with leading immunotherapies were recently initiated in genitourinary cancer indications. The company also retired the final tranche of its remaining corporate debt, and shortly after the close of the second quarter, announced the favorable settlement </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of its dispute with Genentech (a member of the Roche Group) concerning cobimetinib, which Exelixis initiated in June 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;The second quarter of 2017 was highlighted by the growth of the cabozantinib franchise, and the significant clinical development, financial and regulatory progress made by the Exelixis team,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. &#8220;With increasing revenues and disciplined financial management, Exelixis is now funding our growth from our operations, giving us the flexibility to invest in clinical trials, evaluate business development opportunities, and reinitiate measured discovery operations that can build long-term value and benefit the patients we serve.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Morrissey continued: &#8220;Shortly after the quarter closed, Exelixis made an important step forward when we and our partner Genentech agreed to a revised revenue and cost-sharing arrangement for cobimetinib&#8217;s commercialization in the United States. The new terms provide an equitable foundation for our work with Genentech on this important Exelixis-discovered compound that is now the subject of three phase 3 pivotal trials and multiple earlier stage trials.&#8221; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Cabozantinib Highlights</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Strong Growth in Cabozantinib Franchise Net Revenue. </font><font style="font-family:inherit;font-size:10pt;">Cabozantinib generated </font><font style="font-family:inherit;font-size:10pt;">$88.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net product revenue during the second quarter of 2017, an increase of </font><font style="font-family:inherit;font-size:10pt;">28 percent</font><font style="font-family:inherit;font-size:10pt;">&#32;from the first quarter of 2017 and an increase of </font><font style="font-family:inherit;font-size:10pt;">178 percent</font><font style="font-family:inherit;font-size:10pt;">&#32;year-over-year. The year-over-year increase was driven primarily by the continued U.S. uptake of CABOMETYX following U.S. Food and Drug Administration approval in April 2016 as a treatment for patients with advanced RCC who have received prior anti-angiogenic therapy.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Start of Phase 3 Trial of Cabozantinib in Combination with Nivolumab or with Nivolumab and Ipilimumab in Previously Untreated Advanced or Metastatic RCC. </font><font style="font-family:inherit;font-size:10pt;">Shortly after the quarter ended, Exelixis and Bristol-Myers Squibb Company (BMS) announced the initiation of CheckMate 9ER, the phase 3 trial evaluating cabozantinib in combination with two of BMS&#8217; leading immunotherapies, nivolumab and ipilimumab, compared to sunitinib. The trial is planned to enroll 1,014 treatment-na&#239;ve patients, and the primary endpoint is PFS. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Launch of Phase 1b Trial of Cabozantinib with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors. </font><font style="font-family:inherit;font-size:10pt;">In June, Exelixis announced the initiation of the dose-escalation stage of a phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or RCC. The primary objective is to determine the optimal dose and schedule of daily oral administration of cabozantinib when given in combination with atezolizumab to inform the trial&#8217;s subsequent expansion stage. Expansion cohorts will evaluate the selected dose and schedule in four settings, including previously untreated RCC patients, previously untreated, both cisplatinum eligible and ineligible UC patients, and previously treated UC patients.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Continued Progress on Filing in Previously Untreated Advanced RCC. </font><font style="font-family:inherit;font-size:10pt;">During the second quarter,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Exelixis announced that the analysis of the review by a blinded IRC had confirmed the primary efficacy endpoint results of investigator-assessed PFS from the CABOSUN randomized phase 2 trial in patients with previously untreated advanced RCC with intermediate- or poor-risk disease. The company remains on track to file its sNDA for cabozantinib in the third quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CELESTIAL Data Anticipated in the Second Half of 2017. </font><font style="font-family:inherit;font-size:10pt;">CELESTIAL, the ongoing phase 3 pivotal trial of cabozantinib in patients with advanced hepatocellular carcinoma (HCC), continues to progress. Exelixis is tracking events closely and continues to anticipate that the second interim analysis at 75 percent of the required events will be completed in the second half of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cabozantinib and Cobimetinib Data Presentations at the ESMO 2017 Congress.</font><font style="font-family:inherit;font-size:10pt;">&#160;Exelixis-discovered compounds will be the subject of 10 presentations at the ESMO 2017 Congress, which is being held September 8-12, 2017 in Madrid, Spain. Data from CABOSUN, the randomized phase 2 trial of cabozantinib versus sunitinib in patients with previously untreated advanced RCC, have been accepted as a late-breaking abstract at the meeting and will be the subject of a poster discussion on Sunday, September 10th. Other cabozantinib presentations will include an oral presentation of data from the phase 1b trial of cabozantinib, nivolumab, and ipilimumab in advanced genitourinary malignancies, as well as additional analyses of the METEOR trial in advanced RCC. Cobimetinib presentations at the Congress will include two data sets concerning forms of metastatic melanoma.</font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Cobimetinib Highlights</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Settlement of Arbitration Between Exelixis and Genentech Regarding Companies&#8217; Collaboration Agreement for Cobimetinib. </font><font style="font-family:inherit;font-size:10pt;">After the quarter ended, Exelixis announced a settlement of our arbitration with Genentech concerning claims&#160;asserted by Exelixis against Genentech related to the development and commercialization of cobimetinib, the Exelixis-discovered medicine that is marketed as COTELLIC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The revised revenue and cost-sharing arrangement resolves the companies&#8217; dispute pursuant to the arbitration demand filed on June 3, 2016, and aligns both companies&#8217; interests in advancing cobimetinib as a promising therapy for patients with multiple forms of cancer.  Moving forward, the revenue applied to the profit and loss statement for the COTELLIC collaboration (Collaboration P&amp;L) will now be calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC. Exelixis will continue to share U.S. commercialization costs, while Genentech&#8217;s portion of these costs will now be allocated to the Collaboration P&amp;L in proportion to the number of Genentech products in any given combination including COTELLIC. For more detail on the terms, please see Exelixis&#8217; press release and corresponding Form 8-K filed with the U.S. Securities and Exchange Commission (SEC), both issued on July 20, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cobimetinib Now the Subject of Three Phase 3 Pivotal Trials. </font><font style="font-family:inherit;font-size:10pt;">Roche recently confirmed it anticipates enrolling the first patient in IMspire170, the phase 3 pivotal trial of cobimetinib and atezolizumab versus pembrolizumab in first-line BRAF wild-type metastatic or unresectable locally advanced melanoma, in the third quarter of 2017. Alongside the fully enrolled IMblaze370 trial (third-line advanced or metastatic colorectal cancer) and the currently recruiting IMspire150 TRILOGY (first-line BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma), cobimetinib is now the subject of three phase 3 pivotal trials where it is being evaluated in combination with other anticancer therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Corporate Highlights</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Last Source of Indebtedness Retired Through Repayment of the Deerfield Notes. </font><font style="font-family:inherit;font-size:10pt;">In June 2017, Exelixis retired a series of Secured Convertible Notes originally issued in July 2010 to entities associated with Deerfield Management Company, L.P. (Deerfield Notes). Exelixis retired the Deerfield Notes by making a $123.8 million payment to the Deerfield entities. Repaying the Deerfield Notes a year ahead of their July 2018 maturity date will save Exelixis approximately $12 million in interest expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Presence for Cabozantinib and Cobimetinib at the 2017 ASCO Annual Meeting.</font><font style="font-family:inherit;font-size:10pt;">&#32;Exelixis-discovered compounds were the subject of 13 presentations, including further analysis of the METEOR study in advanced RCC, as well as updated results from the phase 1b combination trial of cabozantinib plus immunotherapy in genitourinary tumors. Additional cabozantinib data presentations included results from trials in endometrial cancer and uterine carcinosarcoma. Cobimetinib data included updates from the early stage combination trials of cobimetinib plus atezolizumab, and plus atezolizumab and vemurafenib, which have informed the design of several of Roche&#8217;s ongoing phase 3 pivotal trials.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2017 Financial Guidance</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company is reiterating its previously provided guidance that total costs and operating expenses for the full year will be between $290 million and $310 million.&#160; This guidance includes approximately $25 million of non-cash costs and expenses related primarily to stock-based compensation expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Second Quarter 2017 Financial Results</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue </font><font style="font-family:inherit;font-size:10pt;">for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$99.0 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$36.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Total revenue includes </font><font style="font-family:inherit;font-size:10pt;">$88.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of net product revenue and collaboration revenue, respectively, compared to </font><font style="font-family:inherit;font-size:10pt;">$31.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The increase in net product revenues primarily reflects the impact of the commercial launch of CABOMETYX in late April 2016. Collaboration revenues for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;include </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;earned under our collaboration agreements with Ipsen, Takeda and Genentech, respectively. In comparison, during the quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, collaboration revenues include </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;earned under our collaboration agreements with Ipsen and Genentech, respectively. </font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and development expenses</font><font style="font-family:inherit;font-size:10pt;">&#32;for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$28.2 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The increase in research and development expenses was primarily a result of increases in clinical trial costs and personnel expenses. The clinical trial cost increase was predominantly due to increases in costs related to CABOSUN, start-up costs associated with CheckMate 9ER, and start-up costs associated with Exelixis&#8217; phase 1b trial of cabozantinib and atezolizumab in locally advanced or metastatic solid tumors, and were partially offset by a decrease in costs related to METEOR. The increase in personnel-related expenses was primarily a result of an increase in headcount associated with the re-launch of our discovery program and the build-out of our medical affairs organization. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selling, general and administrative expenses</font><font style="font-family:inherit;font-size:10pt;">&#32;for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$40.7 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$35.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The increase in selling, general and administrative expenses was primarily a result of increases in personnel expenses resulting primarily from an increase in headcount connected with the build-out and support of the Exelixis U.S. commercial organization, an increase in legal costs, and an increase in consulting and outside services to support our marketing activities. Those increases were partially offset by a decrease in losses under the collaboration agreement with Genentech driven by Genentech&#8217;s change in cost allocation approach in January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other expense, net </font><font style="font-family:inherit;font-size:10pt;">for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was a net expense of </font><font style="font-family:inherit;font-size:10pt;">$8.9 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$9.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The decrease in other expense, net, was primarily due to a decrease in interest expense as a result of the 2016 conversions and redemption of the 4.25% Convertible Subordinated Notes due 2019 and the repayment of the Silicon Valley Bank term loan in March 2017. The decrease in interest expense was partially offset by a </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;loss on extinguishment primarily related to the prepayment penalty associated with the early repayment of the Deerfield Notes on June 28, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income </font><font style="font-family:inherit;font-size:10pt;">for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$17.7 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">$0.06</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, basic and diluted, compared to a net loss of </font><font style="font-family:inherit;font-size:10pt;">$(34.8) million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">$(0.15)</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, basic and diluted, for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The decrease in net loss was primarily due to the increase in net product and collaboration revenues, partially offset by the increase in operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash </font><font style="font-family:inherit;font-size:10pt;">and cash equivalents, short- and long-term investments and long-term restricted cash and investments totaled </font><font style="font-family:inherit;font-size:10pt;">$380.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, as compared to </font><font style="font-family:inherit;font-size:10pt;">$479.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exelixis adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">. For convenience, references in this press release as of and for the fiscal periods ended&#160;June 30, 2017, December 30, 2016&#160;and July 1, 2016 are indicated as being as of and for the periods ended&#160;June 30, 2017, December 31, 2016 and June 30, 2016, respectively. </font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Conference Call and Webcast</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exelixis management will discuss the company&#8217;s financial results for the second quarter of 2017 and provide a general business update during a conference call beginning at 5:00 p.m. EDT/2:00 p.m. PDT today, Wednesday, August 2, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To access the webcast link, log onto </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.exelixis.com</font><font style="font-family:inherit;font-size:10pt;">&#32;and proceed to the Event Calendar page under Investors &amp; Media. Please connect to the company&#8217;s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call (855) 793-2457 (domestic) or (631) 485-4921 (international) and provide the conference call passcode 49002905 to join by phone.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A telephone replay will be available until 11:59 p.m. EDT on Friday, August 4, 2017. Access numbers for the telephone replay are: (855) 859-2056 (domestic) and (404) 537-3406 (international); the passcode is 49002905. A webcast replay will also be archived on&#160;</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.exelixis.com</font><font style="font-family:inherit;font-size:10pt;">&#32;for one year.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">About Exelixis</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since its founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including VEGF, MET, AXL and RET receptors: CABOMETYX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;tablets approved for previously treated advanced renal cell carcinoma and COMETRIQ</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, is a formulation of cobimetinib, a reversible inhibitor of MEK, is marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer and are the subjects of broad clinical development programs. For more information about Exelixis, please visit </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.exelixis.com</font><font style="font-family:inherit;font-size:10pt;">&#32;or follow @ExelixisInc on Twitter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Forward-Looking Statements</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis&#8217; focus on maximizing the opportunity for cabozantinib and cobimetinib to help patients with cancer around the world; the commercialization of CABOMETYX as Exelixis&#8217; top priority; the drivers for Exelixis&#8217; future growth; Exelixis&#8217; plan to submit a sNDA in the third quarter of 2017 for cabozantinib as a treatment for previously untreated patients with advanced RCC; the anticipated timing for the second interim analysis of CELESTIAL in the second half of 2017; future data presentations from clinical trials of cabozantinib and cobimetinib at the ESMO 2017 Congress; the anticipated timing of enrollment for IMspire170; Exelixis&#8217; guidance for 2017 total costs and operating expenses, including non-cash costs and expenses; and the therapeutic potential and continued development of cabozantinib and cobimetinib. Words such as &#8220;focused,&#8221; &#8220;priority,&#8221; &#8220;future,&#8221; &#8220;planned,&#8221; &#8220;anticipated,&#8221; &#8220;will,&#8221; &#8220;guidance,&#8221; &#8220;committed,&#8221; &#8220;potential,&#8221; or other similar expressions identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the degree of market acceptance of CABOMETYX, COMETRIQ, and COTELLIC and the availability of coverage and reimbursement for these products; the risk that unanticipated developments could adversely affect the commercialization of CABOMETYX, COMETRIQ, and COTELLIC; Exelixis&#8217; dependence on its relationship with&#160;its collaboration partners, including, the level of their investment in the resources necessary to successfully commercialize cabozantinib and cobimetinib in the territories where they are approved; risks and uncertainties related to regulatory review and approval processes and Exelixis&#8217; compliance with applicable legal and regulatory requirements;&#160;Exelixis&#8217; ability and the ability of its collaborators to conduct clinical trials of cabozantinib and cobimetinib both alone and in combination with other therapies sufficient to achieve a positive completion; risks related to the potential failure of cabozantinib </font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and cobimetinib, both alone and in combination with other therapies, to demonstrate safety and efficacy in clinical testing; the level of costs associated with Exelixis&#8217; commercialization, research and development and other activities; Exelixis&#8217;&#160;dependence on third-party vendors; Exelixis&#8217; ability to protect the company&#8217;s intellectual property rights; market competition; changes in economic and business conditions, and other factors discussed under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; quarterly report on Form 10-Q filed with the&#160;SEC on&#160;May 1, 2017, and in Exelixis&#8217; future filings with the&#160;SEC, including, without limitation, Exelixis&#8217; quarterly report on Form 10-Q expected to be filed with the SEC on August 2, 2017. The forward-looking statements made in this press release speak only as of the date of this press release.&#160;Exelixis&#160;expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis&#8217; expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-see attached financial tables-</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,717</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenues</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,679</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,014</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,560</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,217</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,727</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,823</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring (recovery) charge</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,950</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,136</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,299</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,271</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense, net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income and other, net</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">951</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,259</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,451</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,741</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,876</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,702</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,228</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,790</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing basic net income (loss) per share </font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,310</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,029</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,860</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing diluted net income (loss) per share </font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,860</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEET DATA</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;text-indent:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016 </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and investments </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">380,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304,568</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,215</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">516,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,511</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,318</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">_______________________________________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">&#32;(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derived from the audited consolidated financial statements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">&#32;(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Cash and investments include cash and cash equivalents, short- and long-term investments and long-term restricted cash and investments. Long-term restricted cash and investments totaled </font><font style="font-family:inherit;font-size:9pt;">$4.7 million</font><font style="font-family:inherit;font-size:9pt;">&#32;as of </font><font style="font-family:inherit;font-size:9pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:9pt;">&#32;and </font><font style="font-family:inherit;font-size:9pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:9pt;">. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"># # #</font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exellogo2017q1a01.gif
<TEXT>
begin 644 exellogo2017q1a01.gif
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MD$F>D4R>D4J@DDV@DDZAE%&BE5*DEU2CEE*DF%6DF%JFF5JHFUVHFUVHG'^
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MC.(HZ+#'+OOLM-=N^^VXYZ[[[KSW[OOO"&7SQANR#,3,&W*T,Q D;]11CT"
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MI2YWR<M>^O*7P RF,(=)S&(:\YC(3*8RE\G,9CH$*(PXR$GR]8].;64@\!B
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MI06P( 8CI"008;RJ!8S A"$*(9!\%+8%JB@&(UYE4X.L(P$#T.A!W+,P:1A
M @GA!PG(2A 'O8Y,T=06>P5"*101I+ =RLP)^*0.%N3U'Y[P2D& 0C7!+B6S
M)_"!(6  (A'MXS\=&.\<C$I>@<B )XE(! E ( '+#N0_'L"N0(9*D'Q<3;\D
M;@$A"-&" 1A :?;860^$48D-[(P4 L&&K0JRV,T=A+<(P6N^*$6"4Y "!CN3
MP4 @3)!.B4D=T7I #@SQ@Q"XX_\?W>U9"W*PB4TL-@:R^I#3.)N#&5S&7"'
M1"AX,( $ !0 *SA(/@AMV),2 LS#J*9LWPH 'B"D&(OPIV'-F1 %$^09#$B
M(4*QV!:PA1\HQH0P,!&M!8<E! /@02A\(P%\>OC6N,ZUKOEZCL3N^M<$@?4#
M6B"GS + P9(;<@Z(,P!D'PG*!%$7L@TB#:+QY*4#2?)G$(")U0HD,XIH"#]&
M4 !H$,0F^)3  /1"'+T)9"?Y.<G""'*DW@H- .OF"@ 24"T=: 9@ZI:5*@"
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M> DA4+7HBK#R !YP E8X$,+PB-:&+,(8 IGP$*'@ * A "I0"<>@#AYX"3
MC* QB-AT A8E$ YW GMX$)0! UQ8"(<W  ]0".)S&YO@ ;BH #5 )(PP #6P
MA!?1AYRXCY.6$:C&'P] = B!# 7(+AWQ+I\1+PRA#E@W$?,"&O7R$?<"&M14
M$0/"'^:8$#H( "? =Q1A,.\A$<D( -S($/B@#M-3$>D@:O_0 @"&"I$B:5#6
M 1#8%HE@@0G_L!77,#C_P ,+  \;HC2I0B#?,AD 0A2D("T\@(\8@9#_QA#"
M,"&^4A$/^1D1*5-[,A14R!\#8&7+,C 5P0^)0(2AT0))!Q*8 "(PL G()0V?
M8#@ T &\IQ3%0"LEP C(4 W2< H\ "(\@( ;H8\]\QA; P 3 "/VL!/%X0$>
M:1%.J9!"!0!322>X")'"DI4>D0^+=93_\ R(>"X? 9+D(E.%!2MQU12%0)(?
MX0D#P"UTD0^1&(4;H9@ 8(D.40T7,P!SN1"=0):V21&/.1'VX!E"\1!5"0!7
MV1":&2L+,9&?49$301D\DPX.P0\)$QH/\!H7(9H1 0^O,FT.,0K%_V%:;P$-
M"0!W$Y$# V!^;;&9_/B>\!D:D$D6\-E4IT66G$B>X/B9\<F/\SD01]*?F_B?
M A&;FZ@!"*@M[RF4"J&@\+E-P!>?)7D0VG8"8,:59+D!F*!)<)%D7M45_Q(*
M'>  *N 3ZMD,80$!(1 3,\!2B< /T=":DB, 8G>%-LI+VF*._."(GT$ =:@.
M._%/_R -><@SWT@F-L"4-[JD3-JD3OJD4!JE4OH1?_1(D4! 3!01<D! US.E
M";@,=M0*_] *%$ '1F !%Z0&3S0V:GH$]< /3H !?#!$_4 .;+1( [$,!.0*
M8SI'0U !S/ /:?!$"W&E%R +RI"HM' !%/\@" 4A"VPD!!3P!1SZ#^+ J':0
MJ(F*!110!1Q:I8$T2 71#VU  1AP 16P"@;12( T$'9 0%IP"_K0$(Y 0)&
M$/$@J5 PJP+1#G:T!!RZ2A30!P-!IA3 IP*A!P1T05[:K,[ZK- :K=(ZK=1:
MK=9ZK=B:K=JZK28(#]C8 2&  \PW$.? 9N/87I5P AM ; OA&P/PKO!:<$F1
M4BU@ !,B  .P 6YH%/R 48TI$*1@KQ/*K<)4# D@ =0I35!1$&1&$"X  +LY
M$)1B".=0L17;(OR #(F0 ]EX5&&Q,SD@#5+%8PFQ6%'G :!U-5;%$RD)CJ50
M"#:P$^@)5B!0$"/_0&#_L"$D,#8^ME;@Q  ("P_PH X[(G87Z+/\)1#BH@+$
MT+1-^Q]>2;!2.[546[56VZ$:0)*U(0SLJ1'"8 C(0;(-81X&D GGDP^G@*(@
ML5B)$ UNZ[;%:!0FD0. 613C0!Q:.!KP8 K<]#-N@@@,H2Z-I0J^YP$UTC"?
MX6K_4 T)D ",$%"&52T9M@&A$ VAL#-":0_1PG,W>1;4F@_1H@F$UW\&\3-P
M-UD^IX[B8P^AEC5B:Q4_UA#IL#-E%0J-FP.>( PG85I2]@!4!@!12Q!8YEL#
M8&[D"FLM0 FJH A%V+ "868"01G79!!Q%AS/T )VT@%XLE@1N[B&E5B=_]"/
M< .-9YE3FF=41C4AXQIS&VL(R/ S-+"XA38#-%"_ ]8!-' =#580.Q%^XF*X
M Z$.$B  X9=AZ )-5PNER  #VIG #OS P/8,"Y  W9NS#0A*K=@NE/$""#$<
M!B"0L,$ U+5? .") P$4#)H06L530VH $\"A__%-ZI  (PPE/\4/#Y 7^N::
M$(QKA<5\L)8,")$9'?8SJ$(/"0"A3J5A!-$5IUD0ZC  #+"'9#('XL8"N4=I
M-C5P!=<53A@-3G,9J3>]82$D?W@0%[*SQLB1)Y-AUY24J!(M.?</7#P0[D%S
M_P#&(,"K/=S'?OS'@,RM\+ KYSH0C0  -4H02?])QFDQ *D8*AHP 'KCG1N
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M #ECCQ:00BGY8 0 'O"C'   !AL P#,.8@@ X$ @V+B*,"#R _\ - @TH7B
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MA2GXC+@>!+UA=PNQ*>U!1MK@(41AP X1HI!&="0?V\6OAX="68$T$-CP>,
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MIW;H'I,+!M[FSI"&J.5@ABC:S@!ICQBPKW:,L : L?:,LEZ(L\X,D)@)K$@
MU*;GGW",J.L*+2N-\!6)%FAA1J)._P+K#OVKCJ*3AGI8@!60K0[.@1;:3B+&
MU\:0!I^H;,\X!)HP :)VC'*V 57 [NS6;E4@!4, 2=!N#-$F[<XP;74:C2U%
M"^> :\T@!8!>[845C19(@'QX!B.%,4,X(G=@6?&XCJR,+W[ !!C( 0E*(/V
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MN^I7SWJ_*T(A@J@#V39)  /&DP^B'*,@^?#  -1AZ>G\0QH#2('<KW4.HN1
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MRXGR/TS$W;HA@<! (G")! 1C(JL"(R0F2$[H PC@1BB$$_^# 71P08S+K'0
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M091B<M"H(3 "*>0F2IC"3[8(#@2(/:C ')#"*?S'!;L#_OY#67< 4NLY?4P
MEH$"O%0#ETAI-6 #-B!#(@2SGA%$,A_$?^QV1<H8EET")-T#"TB SL* ]RHL
MIF6$1(S:4\" JRL(2]#_&5&@,YUBPS5@PS,P0DZT@$"3NZ?Z;CZD&E$+&0X:
MJ;#KQP H0+ARR9$+&9!11C,?=(V5&NV=@[]B1*K%\(X&Z- !/#]0QC<']\4E
M6Y-1H#UH  "D.P1'1BEJ&3RX0$/X ",(F8#_B4 $/']H"2!_G %< T;X-4%4
M P"$@$T5M>A!1%R+>7SRG9:R'P!D@GPW@ &$*P X@):10@%(@'(;!"4+>"H
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61I0XD6)%BQ<Q9M2XD6-'CQ\]!@0 .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
